New directions in the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): shifting from symptom management to targeting tumors

Clin Adv Hematol Oncol. 2014 Dec;12(12 Suppl 19):12-7.
No abstract available

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents, Hormonal / therapeutic use*
  • Everolimus
  • Gastrointestinal Neoplasms / drug therapy
  • Gastrointestinal Neoplasms / surgery
  • Gastrointestinal Neoplasms / therapy*
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Neuroendocrine Tumors / drug therapy
  • Neuroendocrine Tumors / surgery
  • Neuroendocrine Tumors / therapy*
  • Octreotide / therapeutic use
  • Pancreatic Neoplasms / drug therapy
  • Pancreatic Neoplasms / surgery
  • Pancreatic Neoplasms / therapy*
  • Peptides, Cyclic / therapeutic use
  • Sirolimus / analogs & derivatives
  • Sirolimus / therapeutic use
  • Somatostatin / analogs & derivatives
  • Somatostatin / therapeutic use
  • Surgical Procedures, Operative*

Substances

  • Antineoplastic Agents, Hormonal
  • Immunosuppressive Agents
  • Peptides, Cyclic
  • lanreotide
  • Somatostatin
  • Everolimus
  • Octreotide
  • Sirolimus